United Therapeutics (UTHR) Other Non-Current Liabilities (2009 - 2026)

United Therapeutics has disclosed Other Non-Current Liabilities across 18 years of filings, most recently posting $212.0 million for Q2 2026.

• In Q2 2026, Other Non-Current Liabilities rose 2.27% year-over-year to $212.0 million; the TTM figure through Jun 2026 stood at $212.0 million (up 2.27% YoY), while the FY2025 annual figure was $223.2 million, up 22.7% from the prior year.
• Other Non-Current Liabilities came in at $212.0 million for Q2 2026 at United Therapeutics, down from $214.0 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $223.2 million in Q4 2025 to a low of $67.4 million in Q3 2023.
• Average Other Non-Current Liabilities over 5 years is $141.3 million, with a median of $104.0 million recorded in 2022.
• Year-over-year, Other Non-Current Liabilities plunged 34.88% in 2023 and soared 133.8% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $104.6 million in 2022, then fell by 25.62% to $77.8 million in 2023, then soared by 133.8% to $181.9 million in 2024, then gained by 22.7% to $223.2 million in 2025, then slipped by 5.02% to $212.0 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $212.0 million in Q2 2026, $214.0 million in Q1 2026, and $223.2 million in Q4 2025.